Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 EBITDA Margin % is 36.32% as of Dec. 2025, which is 11% below its 10-year median of 40.97. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 958 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 91.75% on this metric.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fujian Haixi Pharmaceuticals Co EBITDA Margin % Related Terms
Fujian Haixi Pharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co EBITDA Margin % Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EBITDA Margin %
47.68
45.62
34.54
36.32
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
EBITDA Margin %
47.68
45.62
34.54
36.32
HKSE:02637 vs ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a EBITDA Margin % of 36.32% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is 11% below median its historical median of 40.97. Over the past decade, Fujian Haixi Pharmaceuticals Co's EBITDA Margin % has ranged from 34.54 to 47.68. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 958 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Fujian Haixi Pharmaceuticals Co's EBITDA Margin % too high?
Fujian Haixi Pharmaceuticals Co's current EBITDA Margin % of 36.32% is 11% below median its 10-year median of 40.97. Over the past 10 years, this metric has ranged from a low of 34.54 to a high of 47.68. The Drug Manufacturers industry median EBITDA Margin % is 11.93. Fujian Haixi Pharmaceuticals Co's value of 36.32% is 204.4% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #79 out of 958 companies for EBITDA Margin %. This places Fujian Haixi Pharmaceuticals Co in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.93. Fujian Haixi Pharmaceuticals Co's value of 36.32% is 204.4% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own EBITDA Margin % has ranged from 34.54 to 47.68 over the past decade. While the company's 10-year median is 40.97 vs. the industry median of 11.93, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.93, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current EBITDA Margin % of 36.32% is 204.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current EBITDA Margin % is 36.32%, which is 11% below median its own 10-year median of 40.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current EBITDA Margin % of 36.32%. The current EBITDA Margin % is 36.32%, which is 11% below median its 10-year median of 40.97 and 204.4% above the Drug Manufacturers industry median of 11.93. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current EBITDA Margin % is 36.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
